Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2025 16:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary...
December 03, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
November 20, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily...
November 13, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025...
November 11, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
November 07, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune...
November 04, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
October 07, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
October 02, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
September 26, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...